Merit Medical Systems earnings release, July 30, 2026

Merit Medical Systems Inc (MMSI) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

FOR IMMEDIATE RELEASE

MERIT MEDICAL REPORTS SECOND QUARTER 2026 RESULTS AND UPDATES FULL-YEAR 2026 GUIDANCE

Financial Highlights†

† Comparisons above are calculated for the current quarter compared with the second quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

SOUTH JORDAN, Utah, July 30, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three and six-month periods ended June 30, 2026.

“Merit delivered second quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G. Aronson, Merit’s President and CEO. “We experienced improving revenue growth trends across our global business in Q2, as expected, with notable strength in sales to customers in the U.S. which increased 10% year-over-year, well ahead of our expectations. We also delivered improvement in both our non-GAAP operating margin and our non-GAAP earnings per share, which increased by 140 basis points and 18%, respectively, year-over-year.”¹

Ms. Aronson continued: “We have increased our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first half of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. Our team remains focused on delivering our Continued Growth Initiative financial targets for the three-year period ending December 31, 2026, and, in parallel, we are developing our longer-term strategic plan focused on identifying opportunities to better position the company for sustainable growth, enhanced profitability and value creation for our shareholders.”

Merit’s revenue by product category for the three and six-month periods ended June 30, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):

​²

Financial Summary:

GAAP gross margin was 51.4%, compared to 48.2% for the second quarter of 2025. Non-GAAP gross margin* was 55.8%, compared to 53.2% for the second quarter of 2025.

GAAP operating margin was 14.4%, compared to 12.3% for the second quarter of 2025. Non-GAAP operating margin* was 22.6%, compared to 21.2% for the second quarter of 2025.

GAAP net income was $38.8 million, or $0.65 per share, compared to $32.6 million, or $0.54 per share, for the second quarter of 2025. Non-GAAP net income* was $71.3 million, or $1.19 per share, compared to $61.0 million, or $1.01 per share, for the second quarter of 2025.

As of June 30, 2026, Merit had cash and cash equivalents of $448.7 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of June 30, 2026.

Fiscal Year 2026 Financial Guidance

Based upon the information currently available to Merit’s management, for the twelve-month period ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:

​

Revenue and Earnings Guidance*

​

*Percentage figures approximated; dollar figures may not foot due to rounding.

Financial statements

Income Statement

Revenue and Earnings Guidance*

Updated Guidance – Year Ending – December 31, 2026Updated Guidance – % Change – Y/YPrior Guidance(2) – Year Ending – December 31, 2026Prior Guidance(2) – % Change – Y/Y
Total Revenue$1.631 - $1.643 billion8% - 8%$1.612 - $1.634 billion6% - 8%
Non-GAAP Earnings Per Share(1)$4.25 - $4.3511% - 14%$4.01 - $4.155% - 8%

Income Statement

Three Months Ended — (Unaudited, in thousands except per share amounts)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Net sales418,843382,462800,720737,813
Cost of sales203,677197,975400,757381,306
Gross profit215,166184,487399,963356,507
Operating expenses:Selling, general and administrative129,229113,097247,439220,583
Operating expenses:Research and development25,38924,36747,99846,845
Operating expenses:Contingent consideration expense (benefit)145143-341,166
Operating expenses:Total operating expenses154,763137,607295,403268,594
Operating expenses:Income from operations60,40346,880104,56087,913
Other income (expense):Interest income3,7523,7617,6527,551
Other income (expense):Interest expense-12,118-6,775-18,644-13,343
Other income (expense):Other (expense) income — net-723-48711,292-784
Other income (expense):Total other (expense) income — net-9,089-3,501300-6,576
Other income (expense):Income before income taxes51,31443,379104,86081,337
Other income (expense):Income tax expense12,51110,79825,06218,609
Other income (expense):Net income38,80332,58179,79862,728
Earnings per common shareBasic0.650.551.341.06
Earnings per common shareDiluted0.650.541.331.03
Weighted average shares outstandingBasic59,67959,14059,59559,019
Weighted average shares outstandingDiluted60,00660,61160,01060,945

Income Statement

Three Months Ended — (Unaudited, in thousands except per share amounts)

Three Months Ended – June 30, 2026 – Pre-TaxThree Months Ended – June 30, 2026 – Tax ImpactThree Months Ended – June 30, 2026 – After-TaxThree Months Ended – June 30, 2026 – Per Share Impact
GAAP net income51,314-12,51138,8030.65
Cost of SalesAmortization of intangibles18,718-4,41914,2990.24
Operating ExpensesContingent consideration expense145-331120
Operating ExpensesAmortization of intangibles2,496-5891,9070.03
Operating ExpensesPerformance-based share-based compensation (a)6,621-7565,8650.1
Operating ExpensesCorporate restructuring (b)2,159-5101,6490.03
Operating ExpensesAcquisition-related2,568-1942,3740.04
Operating ExpensesMedical Device Regulation expenses (c)1,452-3421,1100.02
Other (Income) ExpenseLong-term debt costs (e)6,477-1,5294,9480.08
Other (Income) ExpenseOther non-operating loss (f)294-822120
Other (Income) ExpenseNon-GAAP net income92,244-20,96571,2791.19
Other (Income) ExpenseDiluted shares60,006

Income Statement

Three Months Ended — (Unaudited, in thousands except per share amounts)

Three Months Ended – June 30, 2025 – Pre-TaxThree Months Ended – June 30, 2025 – Tax ImpactThree Months Ended – June 30, 2025 – After-TaxThree Months Ended – June 30, 2025 – Per Share Impact
GAAP net income43,379-10,79832,5810.54
Cost of SalesAmortization of intangibles18,980-4,48514,4950.24
Cost of SalesInventory mark-up related to acquisitions67-16510
Operating ExpensesContingent consideration expense143251680
Operating ExpensesAmortization of intangibles2,543-6011,9420.03
Operating ExpensesPerformance-based share-based compensation (a)5,879-3455,5340.09
Operating ExpensesCorporate restructuring (b)2,587-6111,9760.03
Operating ExpensesAcquisition-related2,140-142,1260.04
Operating ExpensesMedical Device Regulation expenses (c)1,634-3851,2490.02
Operating ExpensesOther (d)50-12380
Other (Income) ExpenseLong-term debt costs (e)1,414-3341,0800.02
Other (Income) ExpenseGain on disposal of business unit-249-2490
Other (Income) ExpenseNon-GAAP net income78,567-17,57660,9911.01
Other (Income) ExpenseDiluted shares60,611

Income Statement

Six Months Ended — (Unaudited, in thousands except per share amounts)

Six Months Ended – June 30, 2026 – Pre-TaxSix Months Ended – June 30, 2026 – Tax ImpactSix Months Ended – June 30, 2026 – After-TaxSix Months Ended – June 30, 2026 – Per Share Impact
GAAP net income104,860-25,06279,7981.33
Cost of SalesAmortization of intangibles36,945-8,72228,2230.47
Operating ExpensesContingent consideration benefit-345-290
Operating ExpensesAmortization of intangibles4,950-1,1683,7820.06
Operating ExpensesPerformance-based share-based compensation (a)12,429-1,06211,3670.19
Operating ExpensesCorporate restructuring (b)2,159-5101,6490.03
Operating ExpensesAcquisition-related6,811-9055,9060.1
Operating ExpensesMedical Device Regulation expenses (c)2,070-4881,5820.03
Other (Income) ExpenseLong-term debt costs (e)7,891-1,8636,0280.1
Other (Income) ExpenseGain on disposal of business unit-12,5021,520-10,982-0.18
Other (Income) ExpenseOther non-operating loss (f)825-2076180.01
Other (Income) ExpenseNon-GAAP net income166,404-38,462127,9422.13

Income Statement

Six Months Ended — (Unaudited, in thousands except per share amounts)

Six Months Ended – June 30, 2025 – Pre-TaxSix Months Ended – June 30, 2025 – Tax ImpactSix Months Ended – June 30, 2025 – After-TaxSix Months Ended – June 30, 2025 – Per Share Impact
GAAP net income81,337-18,60962,7281.03
Cost of SalesAmortization of intangibles36,586-8,64527,9410.46
Cost of SalesInventory mark-up related to acquisitions67-16510
Operating ExpensesContingent consideration expense1,166341,2000.02
Operating ExpensesAmortization of intangibles4,937-1,1673,7700.06
Operating ExpensesPerformance-based share-based compensation (a)10,653-9319,7220.16
Operating ExpensesCorporate restructuring (b)2,587-6111,9760.03
Operating ExpensesAcquisition-related2,156-182,1380.04
Operating ExpensesMedical Device Regulation expenses (c)3,228-7622,4660.04
Operating ExpensesOther (d)29-7220
Other (Income) ExpenseLong-term debt costs (e)2,828-6682,1600.04
Other (Income) ExpenseGain on disposal of business unit-249-2490
Other (Income) ExpenseNon-GAAP net income145,325-31,400113,9251.87
Other (Income) ExpenseDiluted shares60,945

Income Statement

Three Months Ended — (Unaudited, in thousands except percentages)

Three Months Ended – June 30, 2026 – AmountsThree Months Ended – June 30, 2026 – % SalesThree Months Ended – June 30, 2025 – AmountsThree Months Ended – June 30, 2025 – % SalesSix Months Ended – June 30, 2026 – AmountsSix Months Ended – June 30, 2026 – % SalesSix Months Ended – June 30, 2025 – AmountsSix Months Ended – June 30, 2025 – % Sales
Net Sales as Reported418,843382,462800,720737,813
GAAP Operating Income60,40314.4%46,88012.3%104,56013.1%87,91311.9%
Cost of SalesAmortization of intangibles18,7184.5%18,9805.0%36,9454.6%36,5865.0%
Cost of SalesInventory mark-up related to acquisitions670.0%670.0%
Operating ExpensesContingent consideration expense (benefit)1450.0%1430.0%-34-0.0%1,1660.2%
Operating ExpensesAmortization of intangibles2,4960.6%2,5430.7%4,9500.6%4,9370.7%
Operating ExpensesPerformance-based share-based compensation (a)6,6211.6%5,8791.5%12,4291.6%10,6531.4%
Operating ExpensesCorporate restructuring (b)2,1590.5%2,5870.7%2,1590.3%2,5870.4%
Operating ExpensesAcquisition-related2,5680.6%2,1400.6%6,8110.9%2,1560.3%
Operating ExpensesMedical Device Regulation expenses (c)1,4520.3%1,6340.4%2,0700.3%3,2280.4%
Operating ExpensesOther (d)500.0%290.0%
Operating ExpensesNon-GAAP Operating Income94,56222.6%80,90321.2%169,89021.2%149,32220.2%

Balance Sheet

December 31, — (in thousands)

June 30, – 2026 – (Unaudited)December 31, – 2025
Current AssetsCash and cash equivalents448,699446,404
Current AssetsTrade receivables, net224,237203,710
Current AssetsOther receivables23,96017,773
Current AssetsInventories374,112333,705
Current AssetsPrepaid expenses and other assets33,49631,493
Current AssetsPrepaid income taxes5,0334,941
Current AssetsIncome tax refund receivables2,7012,128
Current AssetsTotal current assets1,112,2381,040,154
Current AssetsProperty and equipment, net436,749428,401
Current AssetsIntangible assets, net612,026537,654
Current AssetsGoodwill539,772506,837
Current AssetsDeferred income tax assets7,2007,049
Current AssetsOperating lease right-of-use assets83,77687,600
Current AssetsOther assets71,85978,227
Current AssetsTotal Assets2,863,6202,685,922
Current LiabilitiesTrade payables70,73760,551
Current LiabilitiesAccrued expenses172,185159,486
Current LiabilitiesCurrent operating lease liabilities10,92110,876
Current LiabilitiesIncome taxes payable11,0908,851
Current LiabilitiesTotal current liabilities264,933239,764
Current LiabilitiesLong-term debt736,258734,038
Current LiabilitiesDeferred income tax liabilities39,70419,665
Current LiabilitiesLiabilities related to unrecognized tax benefits2,2482,248
Current LiabilitiesDeferred compensation payable19,29717,542
Current LiabilitiesDeferred credits1,3471,398
Current LiabilitiesLong-term operating lease liabilities72,94276,658
Current LiabilitiesOther long-term obligations47,08710,306
Current LiabilitiesTotal liabilities1,183,8161,101,619
Stockholders' EquityCommon stock783,892763,909
Stockholders' EquityRetained earnings903,828824,030
Stockholders' EquityAccumulated other comprehensive loss-7,916-3,636
Stockholders' EquityTotal stockholders' equity1,679,8041,584,303
Stockholders' EquityTotal Liabilities and Stockholders' Equity2,863,6202,685,922

Cash Flow

Six Months Ended — (Unaudited, in thousands)

Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income79,79862,728
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization61,53860,313
Adjustments to reconcile net income to net cash provided by operating activities:Gain on disposition of a business-12,557-249
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of right-of-use operating lease assets5,7795,766
Full release

(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.03 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.

(2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on April 30, 2026.

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of July 30, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.³

​

CONFERENCE CALL

As previously announced, Merit will hold its investor conference call today, Thursday, July 30, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the second quarter and provide an operational update.

To access the conference call, please pre-register using the following link.

Registrants will receive confirmation with dial-in details.

A live webcast and slide deck will also be available at merit.com.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Merit Medical Systems earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.